15. 封入体筋炎
[臨床試験数:39,薬物数:32(DrugBank:11),標的遺伝子数:11,標的パスウェイ数:119]
Searched query = "Inclusion body myositis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00079768 (ClinicalTrials.gov) | March 2004 | 12/3/2004 | Alemtuzumab to Treat Sporadic Inclusion Body Myositis | Effects of a T Cell-Depleting Monoclonal Antibody, Alemtuzumab, in Patients With Inclusion Body Myositis: A Pilot Clinicopathological Study | Myositis, Inclusion Body | Drug: Alemtuzumab (Campath) | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | 25 Years | 80 Years | Both | 20 | Phase 2 | United States |